Huadao Biotech achieves breakthrough
Print Edition
Huadao (Shanghai) Biopharmaceutical Co Ltd has announced a major advancement in immunotherapy with the approval of its first CAR-T cell therapy for solid tumors. The therapy, HD004, is the world鈥檚 first cellular treatment targeting CLDN18.2-positive advanced solid tumor malignant ascites, marking a significant step towards making CAR-T therapies more accessible in China.
CAR-T cell therapy, a groundbreaking cancer treatment, involves collecting a patient鈥檚 T cells, genetically modifying them to target specific cancer cells, expanding them in the lab and re-infusing them to fight the tumor. Unlike traditional treatments like surgery or radiation, CAR-T therapy offers a more personalized approach to cancer care.
鈥淭his approval is a milestone for Huadao Biotech, as HD004 becomes the company鈥檚 first CAR-T candidate for solid tumor treatment,鈥 said Yu Xuejun, chairman of Huadao Biotech. CLDN18.2, the target for HD004, is highly expressed in certain cancers, including gastric and esophageal cancers, and is associated with poor prognosis. Malignant ascites, a severe complication of advanced tumors, affects 15 percent to 50 percent of patients with late-stage cancers, often leaving them with a median survival of just five to seven months.
The company has also received approval from China鈥檚 National Medical Products Administration for three additional CAR-T candidates targeting B-cell non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia and multiple myeloma.
One of the key challenges facing CAR-T therapies is their high cost. Yu, a physician with extensive clinical experience, is focused on reducing these costs through innovation. In June 2023, Huadao Biotech received approval for its fully automated cell culture system, a first in China. The company claims this domestically produced equipment can lower production costs by up to 70 percent compared to imported alternatives.
鈥淥ur goal is to make CAR-T therapies affordable for the Chinese public,鈥 Yu said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
